SCHEMBL3415836

SCHEMBL3415836

CC(N)OC(=O)C(O)C(O)C(=O)OC(C)N

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.33
HTT P42858 1/20 0.32
SLC7A5 Q01650 1/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5833248 0.83
SCHEMBL13265006 0.80
SCHEMBL19361146 0.80
SCHEMBL7682205 0.79 TSHR (0.31) TSHRHTT
Hydrochloric Acid SCHEMBL3507717 0.78 TSHR (0.33) TSHRSLC7A5
SCHEMBL11669820 0.77 TSHR (0.36) TSHRHTTTP53
SCHEMBL1338978 0.77 TSHR (0.50) TSHRHTTTP53
SCHEMBL8636434 0.77 TSHR (0.50) TSHRHTTTP53
SCHEMBL1336756 0.77 TSHR (0.50) TSHRHTTTP53
SCHEMBL571478 0.77 TSHR (0.50) TSHRHTTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3938045-A1 SALTS OF A ISOCHROMANYL COMPOUND AND CRYSTALLINE FORMS, PROCESSES FOR PREPARING, THERAPEUTIC USES, AND PHARMACEUTICAL COMPOSITIONS THEREOF Sunovion Pharmaceuticals Inc. (US) 2022-01-19 EP disclosed
WO-2020186165-A1 SALTS OF A ISOCHROMANYL COMPOUND AND CRYSTALLINE FORMS, PROCESSES FOR PREPARING, THERAPEUTIC USES, AND PHARMACEUTICAL COMPOSITIONS THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2020-09-17 WO disclosed
CN-105214450-A A kind of selective absorbing SO 2absorbent and absorb SO 2process HUANG RUI 2016-01-06 CN disclosed
US-8258189-B2 Compounds prepared by adding an oxetane derivative to an alcohol CECALC (FR) 2012-09-04 US disclosed
US-20100216894-A1 NOVEL COMPOUNDS PREPARED BY ADDING AN OXETANE DERIVATIVE TO AN ALCOHOL CECALC (FR) 2010-08-26 US disclosed
US-6040372-A Hydrated zinc stannate sols, coating compositions and optical elements NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2000-03-21 US disclosed
US-6001164-A AS MICROFILLERS TO BE USED AS HARD COATING AGENT WITH HIGH REFRACTIVE INDEX TO BE APPLIED ON SURFACE OF PLASTIC LENSES, FILMS OR PLASTIC MOLDED PRODUCTS, OR MAY BE MIXED WITH VARIOUS RESIN EMULSIONS FOR USE AS FLAME RETARDANTS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1999-12-14 US disclosed
US-5891362-A DISPERSED IN LIQUID NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1999-04-06 US disclosed
EP-0748768-A1 Hydrated zinc stannate sols, coating compositions and optical elements NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1996-12-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216894-A1 NOVEL COMPOUNDS PREPARED BY ADDING AN OXETANE DERIVATIVE TO AN ALCOHOL ADH1A, ADH5, ADH1C TSHR 4196/4885HTT 4727/4885SLC7A5 3801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.